-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Iniparib
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/160003-66-7.gif)
| Category | Influenza Virus |
| CAS | 160003-66-7 |
| Description | BSI-201 is a small-molecule prodrug inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) with potential chemosensitizing, radiosensitizing and antineoplastic activities. In vivo, PARP-1 inhibitor BSI-201 is converted to the active drug, which selectively binds to PARP-1 and inhibits PARP-1- mediated DNA repair. Consequently, this agent may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. In addition, PARP-1 inhibitor BSI-201 may exhibit direct antineoplastic activity against cancers defective in DNA repair. PARP-1 catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks. |
Product Information
| Synonyms | BSI-201; BSI201; BSI 201; NSC746045; NSC-746045; NSC 746045; ND-71677; NIBA; INO-2BA; SAR-240550; IND-71677. IND 71677; IND71677; Iniparib |
| IUPAC Name | 4-iodo-3-nitrobenzamide |
| Molecular Weight | 292.032 |
| Molecular Formula | C7H5IN2O3 |
| Canonical SMILES | C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I |
| InChI | InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11) |
| InChIKey | MDOJTZQKHMAPBK-UHFFFAOYSA-N |
| Boiling Point | 344.8±32.0 °C at 760 mmHg |
| Flash Point | 162.3±25.1 °C |
| Purity | 99.82% |
| Density | 2.1±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 100 mg/mL(342.43 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.56 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.56 mM); Clear solution |
| Appearance | Light yellow to yellow (Solid) |
| Application | Poly(ADP-ribose) Polymerase Inhibitors |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 228 |
| Exact Mass | 291.93449 |
| Index Of Refraction | 1.696 |
| In Vitro | Iniparib non-selectively modifies cysteine-containing proteins in tumor cells. Iniparib (100 μM) weakly inhibits SSB repair, and inhibition can be reversed by knocking down PARP1. The combination of iniparib with cisplatin has EMT-altered cytotoxicity to Myc/MDA-231. |
| PSA | 88.91000 |
| Target | PARP; Influenza Virus |
| Vapor Pressure | 0.0±0.8 mmHg at 25°C |
| XLogP3-AA | 1.3 |
